AQR Capital Management LLC Lowers Stake in Organogenesis Holdings Inc. (NASDAQ:ORGO)

AQR Capital Management LLC cut its stake in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 43.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,522,154 shares of the company's stock after selling 1,188,452 shares during the quarter. AQR Capital Management LLC owned 1.21% of Organogenesis worth $4,871,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Barclays PLC raised its stake in Organogenesis by 251.7% in the third quarter. Barclays PLC now owns 94,809 shares of the company's stock worth $271,000 after buying an additional 67,855 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Organogenesis by 107.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 205,943 shares of the company's stock worth $589,000 after acquiring an additional 106,823 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Organogenesis by 54.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 2,950,849 shares of the company's stock valued at $9,443,000 after purchasing an additional 1,035,120 shares during the period. SG Americas Securities LLC boosted its position in shares of Organogenesis by 66.4% during the fourth quarter. SG Americas Securities LLC now owns 41,746 shares of the company's stock valued at $134,000 after purchasing an additional 16,660 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in shares of Organogenesis by 7.1% during the fourth quarter. Rhumbline Advisers now owns 115,266 shares of the company's stock valued at $369,000 after purchasing an additional 7,621 shares in the last quarter. 49.57% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Michael Joseph Driscoll sold 25,000 shares of the company's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total transaction of $127,500.00. Following the sale, the director now owns 166,879 shares of the company's stock, valued at $851,082.90. This represents a 13.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 36.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Separately, Morgan Stanley raised their price objective on Organogenesis from $4.00 to $6.00 and gave the company an "equal weight" rating in a research report on Wednesday, March 5th.

Organogenesis Stock Down 1.3%

ORGO traded down $0.04 during midday trading on Wednesday, reaching $3.11. The company's stock had a trading volume of 633,031 shares, compared to its average volume of 1,162,673. The stock's 50-day moving average is $4.54 and its 200-day moving average is $3.91. Organogenesis Holdings Inc. has a 1 year low of $2.28 and a 1 year high of $6.71. The firm has a market capitalization of $394.52 million, a price-to-earnings ratio of -51.83 and a beta of 1.85. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21.

Organogenesis (NASDAQ:ORGO - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by ($0.17). Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. The company had revenue of $86.69 million for the quarter, compared to the consensus estimate of $90.77 million. As a group, research analysts expect that Organogenesis Holdings Inc. will post -0.07 EPS for the current year.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.